Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Trial of Cladribine (CdA) With Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease

NCT00923013 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00923013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00923013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Trial of Cladribine (CdA) With Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 20, 2008
Completion date
January 31, 2030
Enrollment
175 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hairy cell leukemia